Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,245

Document Document Title
WO/2024/040190A1
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...  
WO/2024/038356A1
The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1'-heteroaryl and 1,1'-biheteroaryl compounds, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infections in a pati...  
WO/2024/040109A2
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/037459A1
Provided are a series of amide-containing heterocyclic derivatives and the use thereof, and specifically provided are compounds represented by formula (III) and pharmaceutically acceptable salts thereof.  
WO/2024/032598A1
The present application relates to a TGF-β inhibitor compound and the use thereof. Specifically, disclosed in the present application is a compound as represented by formula (I), or an isotope-labeled compound thereof, or an optical iso...  
WO/2024/036097A1
Provided herein are heteroaromatic macrocyclic ether compounds and isotopologues thereof, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and methods of treating, preventing or man...  
WO/2024/036270A1
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/033277A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...  
WO/2024/032529A1
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...  
WO/2024/032589A1
Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...  
WO/2024/032673A1
A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of rela...  
WO/2024/035627A1
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.  
WO/2024/032702A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.  
WO/2024/034591A1
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer. The present inventors examined compounds useful as an active ingredient of a pharmaceutical com...  
WO/2024/032782A1
Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...  
WO/2024/027695A1
A class of compounds as HER2 inhibitors. Specifically, the present invention relates to compounds as shown in general formula (1), general formula (2) and general formula (3), a preparation method therefor, and the use of the compounds o...  
WO/2024/031089A1
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.  
WO/2024/030647A1
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...  
WO/2024/028411A1
The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.  
WO/2023/235837A3
N-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid derivative-comprising compounds for the inhibition of certain kinases for use in certain kinase-mediated disease states. Pharmaceutical compositions, conjugates, and methods for tre...  
WO/2024/030633A1
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...  
WO/2024/028273A1
The invention relates to novel crystalline forms of (S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyri din-2- yl]-amide, processes for their preparation, medicaments and pharma...  
WO/2024/022362A1
The present invention belongs to the field of agricultural insecticides and particularly relates to a fused ring compound with a sulfur-containing substituent, a preparation method, an insecticide composition, and use. Compared with the ...  
WO/2024/022471A1
The present invention provides a KRAS inhibitor compound and a use thereof, and specifically discloses a heterocyclic compound as shown in formula (I-1) or formula (I-2), a pharmaceutically acceptable salt, a stereoisomer, a deuterated d...  
WO/2024/022244A1
The present application relates to a heterocyclic compound having biological activity represented by formula (I), a preparation method therefor and a pharmaceutical composition thereof, and further relates to an use of such a compound an...  
WO/2024/022167A1
The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...  
WO/2024/022444A1
The present disclosure relates to a fused ring compound, a preparation method therefor and a medicinal application thereof. Specifically, the present disclosure relates to a fused ring compound represented by general formula (IN), a prep...  
WO/2024/026061A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject i...  
WO/2024/019103A1
Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer. Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical compo...  
WO/2024/017392A1
Disclosed in the present invention are a pyrimidine ring compound, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof. The pyrimidine ring compound is a compound as represented by formula (I) or formula (II)...  
WO/2024/020522A1
The present disclosure relates to compounds that act as degraders of IRAK-4 protein kinase; pharmaceutical compositions comprising compounds of Formula (I); and methods of treating diseases and disorders associated with cancer and inflam...  
WO/2024/018403A1
The present disclosure includes substituted imidazoamide compounds of Formula (I), analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the disclosure can be used to treat, ameliorate, and...  
WO/2024/020084A1
Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.  
WO/2024/020068A1
Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...  
WO/2024/020034A1
Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment ...  
WO/2024/017381A1
The present application relates to a compound for inhibiting IRAK4 activity and a use thereof, and specifically provides a compound as represented by formula A, or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer,...  
WO/2024/015503A1
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.  
WO/2024/015497A1
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...  
WO/2024/012512A1
Provided are a carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I), and the carbazole derivative has a condensed carbazole structure. The compound can be applied to an org...  
WO/2024/012519A1
Provided in the present invention are a fused ring aromatic compound having a broad-spectrum inhibition effect on KRAS mutation, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. As shown in formula ...  
WO/2024/012469A1
The present invention relates to a carbazole derivative and use thereof in an organic light-emitting element. The carbazole derivative has a fused carbazole structure, a high triplet state energy level is achieved, and conjugation of a c...  
WO/2024/012456A1
Disclosed are a piperazine bridge-substituted heterocyclic pyrimidine compound or a pharmaceutically acceptable salt thereof. Specifically disclosed is a compound represented by formula (III-1) or a pharmaceutically acceptable salt thereof.  
WO/2024/011883A1
The present invention relates to a WEE1 inhibitor, preparation therefor and a use thereof. The structure of the WEE1 inhibitor is represented by formula (I). The present invention relates to a compound of formula (I), or a stereoisomer t...  
WO/2024/008179A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D.  
WO/2024/008833A1
A prodrug kit for multifactorial dynamic chemotherapy comprises N different small-molecule- drug-conjugates selected from the group comprising Si = Fci―Li―Cti with i = 1, 2, 3, …., 360 wherein 2 ≤ N ≤ 360, Fci is a moiety that ...  
WO/2024/009191A1
The invention relates to compounds of Formula (I)–(VII), or pharmaceutically acceptable salts thereof, to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such pro...  
WO/2024/008178A1
Provided are a compound of formula (I), and a stereoisomer, tautomer, deuterated product or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and an application...  
WO/2024/008068A1
Provided herein are KRAS mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.  
WO/2024/007997A1
Disclosed in the present invention are a crystal form of a pyridone polycyclic derivative and a preparation method therefor, and particularly a crystal form of a compound as represented by formula (I) and a preparation method therefor.  
WO/2024/008088A1
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...  

Matches 1 - 50 out of 9,245